Brendan Smith

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Lexington, MA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Elizabeth Ryland Waldinger, attorney-in-fact
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Brendan Smith

Form 4 holding Chief Financial Officer

CRISPR Therapeutics AG

Security class
Common Shares
Shares / value
5,072
Estimated value
$317,015
Report date
21 Feb 2023
Price
$62.50
Ownership
Direct
Form 4 holding Chief Financial Officer

CRISPR Therapeutics AG

Security class
Restricted Stock Units
Shares / value
11,475
Estimated value
Report date
18 Feb 2023
Price
Ownership
Direct
Underlying class
Common Shares
Underlying amount
Form 4 holding Chief Financial Officer

Translate Bio, Inc.

Security class
Stcok Option (right to buy)
Shares / value
0
Estimated value
Report date
14 Sep 2021
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Brendan Smith

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .